Thyroid Cancer MDx Firm Veractye Raises $28M in Series C Round | GenomeWeb

NEW YORK (GenomeWeb News) – Molecular diagnostics firm Veracyte today announced the final tranche of its Series C financing round raising $28 million.

Proceeds will go toward commercial expansion of its gene expression-based diagnostic tool called Afirma Thyroid FNA Analysis for thyroid cancer and the development of its product pipeline.

GE Ventures was a new investor in the round. Domain Associates, Kleiner Perkins Caufield & Byers, TPG Biotech, Versant Ventures, and all previous investors participated.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.